Takeda Launches Subsidiary in Ecuador  

Takeda Pharmaceuticals International GmbH has launched a wholly-owned subsidiary in Ecuador which will be responsible for the sales and marketing of Takeda’s products in the country.

With a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia and Ecuador, the company is continuing to look at opportunities to further expand its footprint in Latin America. According to IMS Health, pharmaceutical sales in Latin America totaled US$ 74.5 billion in 2012 and are expected to grow at a compound annual rate of 8%* between 2012 and 2016. Takeda plans to outgrow the market over the same period, it reports.

Driven by government investment and strong oil and mining industries., Ecuador represents is a dynamic and growing market The country’s GDP totalled more than US$ 70 billion in 2012 while pharmaceutical sales in amounted to US$1.27 billion and are expected to continue to grow by 10% during 2013*. Takeda is building a product portfolio based on the medical needs of the population, focusing on gastroenterology, cardiology, metabolism, oncology and respiratory diseases.

Carlos Haro, who has been appointed country manager for Ecuador, joins the Company from Sanofi, where he was the General Manager for Ecuador. He will lead the start-up team which will grow steadily as the Company expands its portfolio and enters new therapeutic areas.

“The launch of our subsidiary in Ecuador reinforces Takeda’s position in Latin America and will enable us to meet the diverse healthcare needs of the population. We have an established product portfolio, which will give us a strong starting point and we look forward to launching our novel medicines into the market,” said Norbert Oppitz, Senior Vice President, Latin America, at Takeda “This investment further demonstrates our commitment to Latin America and its growth potential. We have ambitious plans in this region and we continue to evaluate opportunities to expand our footprint.”

*Data Source：© 2012 IMS Health. All rights reserved. Estimate based on Market Prognosis Global 2012-2016.